Abstract
Mesenchymal stem cells (MSCs) have been isolated not only from bone marrow, but also from many other tissues such as adipose tissue, skeletal muscle, liver, brain and pancreas. Because MSC were found to have the ability to differentiate into cells of multiple organs and systems such as bone, fat, cartilage, muscle, neurons, hepatocytes and insulin-producing cells, MSCs have generated a great deal of interest for their potential use in regenerative medicine and tissue engineering. Furthermore, given the ease of their isolation and their extensive expansion rate and differentiation potential, mesenchymal stem cells are among the first stem cell types that have a great potential to be introduced in the clinic. Finally, mesenchymal stem cells seem to be not only hypoimmunogenic and thus be suitable for allogeneic transplantation, but they are also able to produce immunosuppression upon transplantation. In this review we summarize the latest research in the use of mesenchymal stem cells in transplantation for generalized diseases, local implantation for local tissue defects, and as a vehicle for genes in gene therapy protocols.
Keywords: Mesenchymal stem cells, Cell therapy, Transplantation, Immunomodulation, Gene therapy
Current Stem Cell Research & Therapy
Title: Adult Mesenchymal Stem Cells: A Pluripotent Population with Multiple Applications
Volume: 1 Issue: 3
Author(s): Christopher D. Porada, Esmail D. Zanjani and Graca Almeida-Porada
Affiliation:
Keywords: Mesenchymal stem cells, Cell therapy, Transplantation, Immunomodulation, Gene therapy
Abstract: Mesenchymal stem cells (MSCs) have been isolated not only from bone marrow, but also from many other tissues such as adipose tissue, skeletal muscle, liver, brain and pancreas. Because MSC were found to have the ability to differentiate into cells of multiple organs and systems such as bone, fat, cartilage, muscle, neurons, hepatocytes and insulin-producing cells, MSCs have generated a great deal of interest for their potential use in regenerative medicine and tissue engineering. Furthermore, given the ease of their isolation and their extensive expansion rate and differentiation potential, mesenchymal stem cells are among the first stem cell types that have a great potential to be introduced in the clinic. Finally, mesenchymal stem cells seem to be not only hypoimmunogenic and thus be suitable for allogeneic transplantation, but they are also able to produce immunosuppression upon transplantation. In this review we summarize the latest research in the use of mesenchymal stem cells in transplantation for generalized diseases, local implantation for local tissue defects, and as a vehicle for genes in gene therapy protocols.
Export Options
About this article
Cite this article as:
Porada D. Christopher, Zanjani D. Esmail and Almeida-Porada Graca, Adult Mesenchymal Stem Cells: A Pluripotent Population with Multiple Applications, Current Stem Cell Research & Therapy 2006; 1(3) . https://dx.doi.org/10.2174/157488806778226821
DOI https://dx.doi.org/10.2174/157488806778226821 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Effects of Fenofibrate on the Expression of Small Heterodimer Partner (SHP) and Cytochrome P450 (CYP) 2D6
Drug Metabolism Letters Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Drug-induced Cholelithiasis
Current Reviews in Clinical and Experimental Pharmacology Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints
Current Pharmaceutical Design Diabetes, Hyperglycemia and Accelerated Atherosclerosis: Evidence Supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Iron Overload is Associated with Perihematoma Edema Growth Following Intracerebral Hemorrhage that may Contribute to In-hospital Mortality and Long-term Functional Outcome
Current Neurovascular Research Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science Relation Between Obstructive Sleep Apnea Syndrome and Resistant Hypertension - The Tip of the Iceberg
Current Respiratory Medicine Reviews Physiology and Pharmacology of Two-Pore Domain Potassium Channels
Current Pharmaceutical Design Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Theranostic Aspects: Treatment of Cancer by Nanotechnology
Mini-Reviews in Medicinal Chemistry Advanced Glycation and Advanced Lipoxidation: Possible Role in Initiation and Progression of Diabetic Retinopathy
Current Pharmaceutical Design Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Current Pharmaceutical Design